Highland Capital Management LLC decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.5% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 36,299 shares of the company’s stock after selling 2,509 shares during the period. Highland Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $5,774,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of TMO. Mycio Wealth Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 1.6% in the second quarter. Mycio Wealth Partners LLC now owns 711 shares of the company’s stock worth $105,000 after buying an additional 11 shares during the last quarter. Signaturefd LLC boosted its stake in shares of Thermo Fisher Scientific by 10.6% in the second quarter. Signaturefd LLC now owns 842 shares of the company’s stock worth $124,000 after buying an additional 81 shares during the last quarter. Cedar Wealth Management LLC boosted its stake in shares of Thermo Fisher Scientific by 33.0% in the second quarter. Cedar Wealth Management LLC now owns 1,377 shares of the company’s stock worth $203,000 after buying an additional 342 shares during the last quarter. Bridgeway Capital Management Inc. acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth approximately $207,000. Finally, Summit Financial Wealth Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific during the third quarter worth approximately $231,000. 86.28% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) traded up 0.70% during mid-day trading on Tuesday, reaching $141.30. 2,186,608 shares of the company’s stock traded hands. The firm has a 50-day moving average price of $149.29 and a 200-day moving average price of $151.92. The company has a market capitalization of $55.82 billion, a P/E ratio of 28.24 and a beta of 1.24. Thermo Fisher Scientific Inc. has a 1-year low of $119.75 and a 1-year high of $160.68.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, October 27th. The company reported $2.03 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.97 by $0.06. Thermo Fisher Scientific had a return on equity of 14.95% and a net margin of 11.10%. The company had revenue of $4.49 billion for the quarter, compared to analysts’ expectations of $4.39 billion. During the same quarter in the previous year, the business posted $1.80 EPS. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post $8.25 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, January 16th. Shareholders of record on Thursday, December 15th will be paid a dividend of $0.15 per share. The ex-dividend date of this dividend is Tuesday, December 13th. This represents a $0.60 annualized dividend and a yield of 0.42%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 12.00%.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Financial Market News and is the propert of of Financial Market News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be viewed at http://www.financial-market-news.com/highland-capital-management-llc-decreases-stake-in-thermo-fisher-scientific-inc-tmo/1208934/.

A number of brokerages recently commented on TMO. Jefferies Group reissued a “hold” rating on shares of Thermo Fisher Scientific in a research note on Thursday, August 4th. Leerink Swann began coverage on shares of Thermo Fisher Scientific in a research note on Thursday, November 10th. They issued an “outperform” rating and a $175.00 price objective on the stock. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $178.00 price objective on the stock in a research note on Monday, August 1st. JPMorgan Chase & Co. initiated coverage on shares of Thermo Fisher Scientific in a research note on Thursday, September 22nd. They issued an “overweight” rating and a $180.00 price objective on the stock. Finally, Cleveland Research lowered shares of Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a report on Friday, September 9th. Two equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $164.37.

In other news, CEO Marc N. Casper sold 28,797 shares of Thermo Fisher Scientific stock in a transaction dated Friday, September 2nd. The stock was sold at an average price of $151.01, for a total transaction of $4,348,634.97. Following the completion of the sale, the chief executive officer now directly owns 307,444 shares in the company, valued at approximately $46,427,118.44. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 30,000 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, September 1st. The shares were sold at an average price of $151.17, for a total value of $4,535,100.00. Following the sale, the chief executive officer now owns 308,647 shares of the company’s stock, valued at $46,658,166.99. The disclosure for this sale can be found here. Company insiders own 0.52% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

5 Day Chart for NYSE:TMO

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Receive News & Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related companies with MarketBeat.com's FREE daily email newsletter.